Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 3/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1089594 | 0.80 | CA2 (0.44) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL16045520 | 0.79 | TSHR (0.46) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL16046615 | 0.79 | TSHR (0.46) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL278989 | 0.77 | TSHR (0.43) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL9745606 | 0.76 | TSHR (0.39) | TSHRADRA1APDE4DTRPA1LMNA | |
| SCHEMBL1973542 | 0.76 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL20565358 | 0.75 | TSHR (0.53) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL4521664 | 0.75 | TSHR (0.42) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL16046806 | 0.75 | TSHR (0.42) | TSHRADRA1APDE4DLMNACA2 | |
| SCHEMBL7644714 | 0.74 | LMNA (0.48) | TSHRADRA1APDE4DLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2025-06-26 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3237419-B1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS LTD (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2020-10-06 | — | — | US | disclosed |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | ABBVIE INC. | 2019-07-11 | — | — | US | disclosed |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-10077268-B2 | FXR agonists and methods for making and using | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-09-18 | — | — | US | disclosed |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. | 2018-05-03 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| EP-1963331-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1692136-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-4560690-A | ANTISECRETORY AGENTS, HISTAMINE H2-ANTAGONISTS | PFIZER INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4233452-A | TREATMENT AND PREVENTION OF CALCIUM OXALATE UROLITHIASIS | MERCK & CO., INC. (US) | 1980-11-11 | — | — | US | disclosed |
| US-4207329-A | Derivatives of glycolic and glyoxylic acid as inhibitors of glycolic acid oxidase | MERCK & CO., INC. (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793577-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-20250206753-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-10077268-B2 | FXR agonists and methods for making and using | NR1H4, FXR2, FXR1 | TSHR 766/4885ADRA1A 667/4885PDE4D 1239/4885 |
| US-20210139490-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-10167294-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-20190211026-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-20240025914-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | TSHR 280/4885ADRA1A 81/4885PDE4D 852/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | TSHR 271/4885ADRA1A 347/4885PDE4D 2485/4885 |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | TSHR 3988/4885ADRA1A 4577/4885PDE4D 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.